Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is Alto Neuroscience (ANRO) Stock Up +7.47% Today?

Why Is Alto Neuroscience (ANRO) Stock Up +7.47% Today?

Key Takeaways

  • Alto Neuroscience (ANRO) gained 7.47%, or $1.86, to $26.77 in midday trading on Nov. 18, up from a prior close of $24.91.
  • No company press release, SEC filing, analyst action, or clinical update accompanied the move.
  • The rally follows two consecutive declines of roughly 8% each, which cut the share price about 20% from its Nov. 12 close of $31.15.
  • Short interest of about 5.7 million shares, or 14% of shares outstanding, tends to magnify intraday swings in a 30.5 million-share float.
  • Sector and market benchmarks were flat-to-lower, so the gain was stock-specific rather than sector-driven.
  • News Significance Score: 10/100 — no verified news catalyst paired with a move that has recurred repeatedly in recent months.
  • Traders are watching the 200-day moving average near $24.80 as support and the $29.50–$31.15 band as overhead resistance.
  • Deeper detail on Price Targets, Earnings, and Forecast data is available on the dedicated ticker pages.
  • Readers looking for systematic strategies can review Trending AI Robots for currently ranked models.

Opening Summary

Alto Neuroscience, Inc. (ANRO) is a clinical-stage biopharmaceutical company based in Mountain View, California, that uses a precision psychiatry platform built on brain biomarkers to develop treatments for depression, bipolar disorder, treatment-resistant depression, and schizophrenia. Its pipeline includes ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208.

On Nov. 18, the stock traded at $26.77, up $1.86, or 7.47%, from the prior session's close of $24.91. The move is definitively to the upside and unfolded with no accompanying corporate announcement or analyst revision. With the broad market slightly lower and biotech benchmarks roughly flat, the gain reflects internal trading dynamics rather than a fundamental development.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found to explain the session's advance. There was no press release, no 8-K, no clinical data disclosure, and no published rating or price-target change tied to Nov. 18. The most recent company news remains the third-quarter report published Nov. 10, along with routine items such as investor-conference participation and employee inducement grants.

The most consistent technical read is a snap-back after a sharp two-session selloff. Shares fell 8.19% on Nov. 16 and another 8.15% on Nov. 17, pushing the stock down 20% from the Nov. 12 close. The Nov. 17 low of $24.79 landed essentially on the 200-day moving average near $24.80, a level that has repeatedly attracted buyers over the past three months. That confluence of a round-number moving average, an oversold short-term condition, and a 14% short interest in a thin float is a pattern consistent with short covering and dip-buying rather than new information.

Profit-Taking After a Sharp November Run

The pullback that preceded today's bounce looks like profit-taking. Between the Nov. 5 close of $21.87 and the Nov. 12 close of $31.15, the stock climbed 42.4% in six sessions on above-average volume, including a 15% single-day jump on Nov. 6 and an 8.9% gain on Nov. 11. Even after the two-day retreat, shares remain well above their 52-week low of $12.51 and are up more than 80% over the past year. Today's move recovers only about a third of that giveback, which is typical of a rebound within a corrective phase rather than the start of a new leg higher.

Market Context and Trading Activity

Volume was not the story. Roughly 347,000 shares had changed hands by early afternoon, a pace broadly in line with the 20-day average near 598,000 and below the 10-day average of about 723,000. A 7.5% move on unremarkable turnover points to thin liquidity and a modest order imbalance rather than institutional accumulation.

The move also diverged from the tape. The XBI biotech ETF was up about 0.2% intraday, while the IBB large-cap biotech benchmark slipped 0.3% and the SPY S&P 500 proxy declined 0.4%. Both indices had fallen sharply on Nov. 16 alongside a broader risk-off session, which explains part of the stock's earlier weakness but not the outsized bounce.

Technically, the stock reclaimed its 50-day moving average near $26.20 after briefly breaking below it and used the 200-day average as a floor. Intraday resistance near $27.11 and the Nov. 16 high around $29.54 remain the levels to clear.

News Significance Score

The score runs from 0 to 100, where 0 represents no meaningful news and a move that is normal for the stock, and 100 represents transformative news paired with an extreme, rare price move. This event scores 10 out of 100.

The news component is negligible: no verified company-specific catalyst surfaced for the session, and the Q3 update that anchors the fundamental narrative was published a week earlier. The price component is also muted. Today's 7.47% gain is about 2.3 times the stock's average absolute daily move of roughly 3.2% over the last 60 sessions, but moves of that size or larger have occurred seven times in that stretch, including declines of 10.7% and 8.5% and gains of 15.0% and 10.5%. On in-line volume, the two factors combine to a low score.

What Comes Next for ANRO

Attention shifts to the company's 2027 catalyst calendar. Topline Phase 2b data for ALTO-300 in major depressive disorder is expected in the first half of 2027, followed by ALTO-100 in bipolar depression around mid-2027 and the PACE-1 Phase 2b study of ALTO-207 in treatment-resistant depression in the second half of 2027. Management has said a Phase 3 program for ALTO-207 could begin in early 2027 pending FDA alignment.

Financial flexibility is a support: $319.8 million in cash and equivalents is expected to fund operations through 2030, following a $100 million registered direct offering in July 2026 that expanded the share count by nearly 50% year over year. Analyst consensus sits at Strong Buy with an average 12-month target near $38.67, the highest at $60. Risks include further dilution, trial delays, binary clinical outcomes, insider selling earlier in the year, and sensitivity to financing conditions for unprofitable biotech names.

Trending AI Robots

Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so results vary widely across market regimes. Reviewing the ranked list is a practical way to see which models are adapting best to present volatility. Explore the page to compare current leaders before deciding what fits your approach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ANRO

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


Momentum Indicator for ANRO turns positive, indicating new upward trend

ANRO saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator turned positive. In 42 of the 47 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ANRO just turned positive on October 20, 2026. Looking at past instances where ANRO's MACD turned positive, the stock continued to rise in 14 of 17 cases over the following month. The odds of a continued upward trend are 82%.

ANRO moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ANRO crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.

Following a +12.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANRO advanced for three days, in 151 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

The Aroon Indicator entered an Uptrend today. In 118 of 136 cases where ANRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The 10-day RSI Indicator for ANRO moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 18 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 24 of 30 cases where ANRO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

ANRO broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.503) is normal, around the industry mean (3.592). P/E Ratio (-10.845) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ANRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
650 Castro Street
Phone
+1 650 200-0412
Employees
68
Web
https://www.altoneuroscience.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.